Teva Found on Summary Judgment to Infringe Mylan Patent for Perforomist® Inhalation Solution

   Teva Found on Summary Judgment to Infringe Mylan Patent for Perforomist®
                             Inhalation Solution

PR Newswire

PITTSBURGH, July 18, 2013

PITTSBURGH, July 18, 2013 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today
announced that the United States District Court for the Northern District of
West Virginia has granted Mylan's motion for partial summary judgment finding
that the production and marketing of Teva's generic version of Mylan's
Perforomist® Inhalation Solution infringes one of Mylan's Orange Book listed
patents (U.S. Patent No. 6,667,344) on Perforomist. Teva's abbreviated new
drug application (ANDA) for a generic Perforomist has not yet been granted
tentative or final approval by the U.S. Food and Drug Administration.

Trial on the remaining issues in the case is currently scheduled to begin
later this month.

This press release includes statements that constitute "forward-looking
statements," including with regard to litigation. These statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from those
expressed or implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, but are not limited to:
strategies by competitors or other third parties to delay or prevent product
sales; risks inherent in legal and regulatory processes; and the other risks
detailed in the company's periodic filings with the Securities and Exchange
Commission. The company undertakes no obligation to update these statements
for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), 724.514.1968; Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.